{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:51:45Z","timestamp":1787503905581,"version":"build-2736575974"},"reference-count":48,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Investissements d\u2019Avenir","award":["ANR-11-LABX-0021"],"award-info":[{"award-number":["ANR-11-LABX-0021"]}]},{"name":"University of Burgundy-Franche-Comte"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Burgundy-Franche Comte"},{"name":"Fonds Europ\u00e9ens de D\u00e9veloppement R\u00e9gional"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess whether, in type 2 diabetes (T2D) patients, lipidomic abnormalities in high-density lipoprotein (HDL) are associated with impaired cholesterol efflux capacity and anti-inflammatory effect, 2 pro-atherogenic abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and Methods<\/jats:title>\n                    <jats:p>This is a secondary analysis of the Lira-NAFLD study, including 20 T2D patients at T0 and 25 control subjects. Using liquid chromatography\/tandem mass spectrometry, we quantified 110 species of the main HDL phospholipids and sphingolipids. Cholesterol efflux capacity was measured on THP-1 macrophages. The anti-inflammatory effect of HDL was measured as their ability to inhibit the tumor necrosis factor \u03b1 (TNF\u03b1)-induced expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) on human vascular endothelial cells (HUVECs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cholesterol-to-triglyceride ratio was decreased in HDL from T2D patients compared with controls (-46%, P\u2005=\u20050.00008). As expressed relative to apolipoprotein AI, the amounts of phosphatidylcholines, sphingomyelins, and sphingosine-1-phosphate were similar in HDL from T2D patients and controls. Phosphatidylethanolamine-based plasmalogens and ceramides (Cer) were, respectively, 27% (P\u2005=\u20050.038) and 24% (P\u2005=\u20050.053) lower in HDL from T2D patients than in HDL from controls, whereas phosphatidylethanolamines were 41% higher (P\u2005=\u20050.026). Cholesterol efflux capacity of apoB-depleted plasma was similar in T2D patients and controls (36.2\u2005\u00b1\u20054.3 vs 35.5\u2005\u00b1\u20052.8%, P\u2005=\u20050.59). The ability of HDL to inhibit the TNF\u03b1-induced expression of both VCAM-1 and ICAM-1 at the surface of HUVECs was similar in T2D patients and controls (-70.6\u2005\u00b1\u200516.5 vs -63.5\u2005\u00b1\u200518.7%, P\u2005=\u20050.14; and -62.1\u2005\u00b1\u200513.2 vs -54.7\u2005\u00b1\u200517.7%, P\u2005=\u20050.16, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite lipidomic abnormalities, the cholesterol efflux and anti-inflammatory capacities of HDL are preserved in T2D patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgac339","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T09:39:29Z","timestamp":1654076369000},"page":"e3816-e3823","source":"Crossref","is-referenced-by-count":26,"title":["Normal HDL Cholesterol Efflux and Anti-Inflammatory Capacities in Type 2 Diabetes Despite Lipidomic Abnormalities"],"prefix":"10.1210","volume":"107","author":[{"given":"Damien","family":"Denimal","sequence":"first","affiliation":[{"name":"INSERM LN , 21000 Dijon , France"},{"name":"C UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Department of Biochemistry, CHU Dijon Bourgogne , 21070 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Benanaya","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Monier","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Flow Cytometry Platform, F\u00e9d\u00e9ration de Recherche Sant\u00e9 STIC\/DIMACELL, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Simoneau","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Department of Endocrinology and Metabolic Diseases, CHU Dijon Bourgogne , 21070 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Pais de Barros","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Lipidomic Analytical Platform, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7611-9644","authenticated-orcid":false,"given":"Wilfried","family":"Le Goff","sequence":"additional","affiliation":[{"name":"Institute of Cardiometabolism and Nutrition, INSERM-UMR_S1166, Sorbonne Universit\u00e9 , 75013 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-6714","authenticated-orcid":false,"given":"Benjamin","family":"Bouillet","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Department of Endocrinology and Metabolic Diseases, CHU Dijon Bourgogne , 21070 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Department of Endocrinology and Metabolic Diseases, CHU Dijon Bourgogne , 21070 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9320-793X","authenticated-orcid":false,"given":"Laurence","family":"Duvillard","sequence":"additional","affiliation":[{"name":"INSERM LNC UMR1231, Universit\u00e9 Bourgogne-Franche Comt\u00e9 , 21000 Dijon , France"},{"name":"Department of Biochemistry, CHU Dijon Bourgogne , 21070 Dijon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"5","key":"2022081816081466500_CIT0001","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia."},{"issue":"11","key":"2022081816081466500_CIT0002","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bbalip.2013.07.009","article-title":"Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles","volume":"1831","author":"St\u00e5hlman","year":"2013","journal-title":"Biochim Biophys Acta."},{"issue":"9","key":"2022081816081466500_CIT0003","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1161\/ATVBAHA.119.312645","article-title":"HDL (high-density lipoprotein) cholesterol efflux capacity is associated with incident cardiovascular disease in the general population","volume":"39","author":"Ebtehaj","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"25","key":"2022081816081466500_CIT0004","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med."},{"issue":"20","key":"2022081816081466500_CIT0005","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/CIRCULATIONAHA.120.050808","article-title":"High-density lipoprotein anti-inflammatory capacity and incident cardiovascular events","volume":"143","author":"Jia","year":"2021","journal-title":"Circulation."},{"issue":"49","key":"2022081816081466500_CIT0006","doi-asserted-by":"crossref","first-page":"37457","DOI":"10.1074\/jbc.M605823200","article-title":"Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells","volume":"281","author":"Kimura","year":"2006","journal-title":"J Biol Chem."},{"issue":"6","key":"2022081816081466500_CIT0007","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cellsig.2005.07.011","article-title":"Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells","volume":"18","author":"Kimura","year":"2006","journal-title":"Cell Signal."},{"issue":"6","key":"2022081816081466500_CIT0008","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/ATVBAHA.109.184663","article-title":"Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells","volume":"29","author":"McGrath","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"3","key":"2022081816081466500_CIT0009","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00125-006-0574-z","article-title":"The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin: cholesterol acyltransferase","volume":"50","author":"Nobecourt","year":"2007","journal-title":"Diabetologia."},{"issue":"19","key":"2022081816081466500_CIT0010","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1021\/bi992902m","article-title":"The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study","volume":"39","author":"Curtiss","year":"2000","journal-title":"Biochemistry."},{"key":"2022081816081466500_CIT0011","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pharmthera.2015.10.010","article-title":"Therapeutic applications of reconstituted HDL: when structure meets function","volume":"157","author":"Darabi","year":"2016","journal-title":"Pharmacol Ther."},{"issue":"11","key":"2022081816081466500_CIT0012","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J Lipid Res."},{"issue":"9","key":"2022081816081466500_CIT0013","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1194\/jlr.M060285","article-title":"The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties","volume":"56","author":"Schwendeman","year":"2015","journal-title":"J Lipid Res."},{"issue":"9","key":"2022081816081466500_CIT0014","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbalip.2015.05.007","article-title":"Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A","volume":"1851","author":"Rached","year":"2015","journal-title":"Biochim Biophys Acta."},{"key":"2022081816081466500_CIT0015","doi-asserted-by":"crossref","first-page":"27367","DOI":"10.1038\/srep27367","article-title":"Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study","volume":"6","author":"Annema","year":"2016","journal-title":"Sci Rep."},{"issue":"3","key":"2022081816081466500_CIT0016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/ijms20030732","article-title":"Antibodies against the C-terminus of ApoA-1 are inversely associated with cholesterol efflux capacity and HDL Metabolism in subjects with and without type 2 diabetes mellitus","volume":"20","author":"Dullaart","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"9","key":"2022081816081466500_CIT0017","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00125-012-2570-9","article-title":"Advanced glycation end-products (AGEs) and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models","volume":"55","author":"Low","year":"2012","journal-title":"Diabetologia."},{"issue":"5","key":"2022081816081466500_CIT0018","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.metabol.2014.03.001","article-title":"Enhanced cholesterol efflux to HDL through the ABCA1 transporter in hypertriglyceridemia of type 2 diabetes","volume":"63","author":"Yassine","year":"2014","journal-title":"Metabolism."},{"key":"2022081816081466500_CIT0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2017.05.031","article-title":"Pre-\u03b21 HDL in type 2 diabetes mellitus","volume":"263","author":"Shiu","year":"2017","journal-title":"Atherosclerosis."},{"issue":"5","key":"2022081816081466500_CIT0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/ATVBAHA.116.307385","article-title":"Impaired cholesterol efflux capacity of high-density lipoprotein isolated from interstitial fluid in type 2 diabetes mellitus-brief report","volume":"36","author":"Apro","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"10","key":"2022081816081466500_CIT0021","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2337\/db11-0378","article-title":"Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes","volume":"60","author":"Morgantini","year":"2011","journal-title":"Diabetes."},{"issue":"1","key":"2022081816081466500_CIT0022","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-017-0613-8","article-title":"The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation","volume":"16","author":"Ebtehaj","year":"2017","journal-title":"Cardiovasc Diabetol."},{"issue":"3","key":"2022081816081466500_CIT0023","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2014-2979","article-title":"Walk-run training improves the anti-inflammation properties of high-density lipoprotein in patients with metabolic syndrome","volume":"100","author":"Sang","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022081816081466500_CIT0024","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022081816081466500_CIT0025","doi-asserted-by":"crossref","first-page":"101284","DOI":"10.1016\/j.diabet.2021.101284","article-title":"Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins","volume":"48","author":"Verg\u00e8s","year":"2022","journal-title":"Diabetes Metab."},{"issue":"5","key":"2022081816081466500_CIT0026","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/ATVBAHA.117.309287","article-title":"Impairment of the ability of HDL from patients with metabolic syndrome but without diabetes mellitus to activate eNOS: correction by S1P enrichment","volume":"37","author":"Denimal","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7","key":"2022081816081466500_CIT0027","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.tem.2014.05.005","article-title":"High-density lipoprotein subfractions: current views and clinical practice applications","volume":"25","author":"Martin","year":"2014","journal-title":"Trends Endocrinol Metab."},{"issue":"8","key":"2022081816081466500_CIT0028","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1139\/o59-099","article-title":"A rapid method of total lipid extraction and purification","volume":"37","author":"Bligh","year":"1959","journal-title":"Can J Biochem Physiol."},{"issue":"2","key":"2022081816081466500_CIT0029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ymeth.2006.05.004","article-title":"Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry","volume":"39","author":"Bielawski","year":"2006","journal-title":"Methods."},{"key":"2022081816081466500_CIT0030","author":"Duvillard"},{"key":"2022081816081466500_CIT0031","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.atherosclerosis.2015.12.042","article-title":"Major changes in the sphingophospholipidome of HDL in non-diabetic patients with metabolic syndrome","volume":"246","author":"Denimal","year":"2016","journal-title":"Atherosclerosis."},{"key":"2022081816081466500_CIT0032","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.ATV.18.9.1450","article-title":"Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells","volume":"18","author":"Ashby","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"7","key":"2022081816081466500_CIT0033","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","article-title":"HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export","volume":"116","author":"Du","year":"2015","journal-title":"Circ Res."},{"issue":"11","key":"2022081816081466500_CIT0034","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/ATVBAHA.109.194548","article-title":"Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent","volume":"29","author":"Larrede","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"2022081816081466500_CIT0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1161\/CIRCRESAHA.111.300104","article-title":"High-density lipoproteins inhibit vascular endothelial inflammation by increasing 3\u03b2-hydroxysteroid-\u039424 reductase expression and inducing heme oxygenase-1","volume":"112","author":"Wu","year":"2013","journal-title":"Circ Res."},{"issue":"1","key":"2022081816081466500_CIT0036","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1096\/fj.201801245R","article-title":"Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy","volume":"33","author":"Keul","year":"2019","journal-title":"FASEB J."},{"issue":"2","key":"2022081816081466500_CIT0037","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.atherosclerosis.2008.07.047","article-title":"Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins","volume":"204","author":"Patel","year":"2009","journal-title":"Atherosclerosis."},{"issue":"2","key":"2022081816081466500_CIT0038","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-2275(20)33375-7","article-title":"Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells","volume":"40","author":"Baker","year":"1999","journal-title":"J Lipid Res."},{"issue":"7","key":"2022081816081466500_CIT0039","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1074\/jbc.M008725200","article-title":"Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI)","volume":"276","author":"Greene","year":"2001","journal-title":"J Biol Chem."},{"key":"2022081816081466500_CIT0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2840-12-27","article-title":"High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate","volume":"12","author":"Tong","year":"2013","journal-title":"Cardiovasc Diabetol."},{"issue":"2","key":"2022081816081466500_CIT0041","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2337\/db12-0686","article-title":"Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance","volume":"62","author":"Boon","year":"2013","journal-title":"Diabetes."},{"issue":"1","key":"2022081816081466500_CIT0042","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12933-021-01260-3","article-title":"Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study","volume":"20","author":"Yubero-Serrano","year":"2021","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"2022081816081466500_CIT0043","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","article-title":"The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages","volume":"30","author":"de la Llera-Moya","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"10","key":"2022081816081466500_CIT0044","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1161\/ATVBAHA.120.315648","article-title":"Molecular patterns of extreme and persistent cholesterol efflux capacity","volume":"41","author":"El-Ghazali","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2022081816081466500_CIT0045","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/ATVBAHA.115.305504","article-title":"HDL phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL-C and coronary disease","volume":"35","author":"Agarwala","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"11","key":"2022081816081466500_CIT0046","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1161\/01.ATV.17.11.2685","article-title":"HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum","volume":"17","author":"Fournier","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"2022081816081466500_CIT0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1194\/jlr.M300231-JLR200","article-title":"In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux","volume":"45","author":"Yancey","year":"2004","journal-title":"J Lipid Res."},{"issue":"12","key":"2022081816081466500_CIT0048","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1194\/jlr.M500263-JLR200","article-title":"Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin","volume":"46","author":"Subbaiah","year":"2005","journal-title":"J Lipid Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac339\/44117051\/dgac339.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/e3816\/45476668\/dgac339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/9\/e3816\/45476668\/dgac339.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T12:12:56Z","timestamp":1660824776000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/9\/e3816\/6596673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac339","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,6,1]]}}}